title: Serum levels after everolimus-stent implantation and paclitaxel-balloon angioplasty in an infant with recurrent pulmonary vein obstruction after repaired total anomalous pulmonary venous connection.
abstract: Everolimus-eluting stents and paclitaxel-coated balloons are used in the interventional treatment of coronary artery disease in adults to reduce the restenosis rate and in small-vessel disease. Both substances are released into the circulation. We report systemic drug exposure after implantation of one everolimus-eluting stent and dilation with one paclitaxel-coated balloon in an 8-month-old infant, which was used as an innovative therapy for recurrent pulmonary vein stenosis.
authors.affiliation: Department for Pediatric Cardiology and Intensive Care Medicine, Georg-August-University Göttingen, Robert-Koch-Str 40, 37075 Göttingen, Germany. matthias.mueller@med.uni-goettingen.de
authors.forename: Matthias J
authors.initials: MJ
authors.lastname: Müller
authors.forename: Ulrich
authors.initials: U
authors.lastname: Krause
authors.forename: Thomas
authors.initials: T
authors.lastname: Paul
authors.forename: Heike E
authors.initials: HE
authors.lastname: Schneider
mesh_terms: D000792:Angiography; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics; D007231:Infant, Newborn; D008297:Male; D017239:Paclitaxel / Q000493:pharmacokinetics*; D011667:Pulmonary Veins / Q000002:abnormalities* / Q000000981:diagnostic imaging / Q000601:surgery; D011668:Pulmonary Veno-Occlusive Disease / Q000097:blood* / Q000151:congenital / Q000601:surgery; D012008:Recurrence; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus